Introduction Monoclonal antibodies binding the EGFR, such as cetuximab and
panitumumab, have been extensively used as targeted therapy for the treatment of mCRC …

Background Microsatellite instability (MSI) status and tumour-infiltrating lymphocytes (TIL)
are established prognostic factors in colorectal cancer. Previous studies evaluating the …

The microsatellite instability (MSI) phenotype is related to a deficiency of the DNA mismatch
repair (dMMR) system and is observed in 5% of metastatic colorectal cancers (mCRCs) …

Background The determinants of metastasis in mismatch repair deficiency with high levels of
microsatellite instability (MSI-H) in colorectal cancer (CRC) are poorly understood. Here, we …

Background Little is known about prognostic factors of brain metastases (BM) from colorectal
cancer (CRC). HER2 amplification/overexpression (HER2+) was previously described; its …

Colorectal cancer (CRC) is a prevalent gastrointestinal cancer posing significant clinical
challenges. CRC management traditionally involves surgery, often coupled with …

Background Following the development of gender medicine in the past 20 years, more
recently in the field of oncology an increasing amount of evidence suggests gender …

Simple Summary In this literature review, we explore the milestone events from the
discovery of BRAF mutations to present-day clinical intervention strategies. We delve into …

Simple Summary The location of the primary tumor in the right colon, left colon, or rectum
affects the efficacy of biological drugs used in the treatment of metastatic colorectal cancer …

Abstract BRAF V600E-mutant metastatic colorectal cancer represents a distinct molecular
phenotype known for its aggressive biological behavior, resistance to standard therapies …